PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 32677488-0 2020 Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts. Arsenic Trioxide 21-37 arsenite methyltransferase Homo sapiens 41-46 34730462-0 2021 Polymorphisms of the AS3MT gene are associated with arsenic methylation capacity and damage to the P21 gene in arsenic trioxide plant workers. Arsenic Trioxide 111-127 arsenite methyltransferase Homo sapiens 21-26 34730462-7 2021 In our study, we investigate whether polymorphisms of the AS3MT gene alter As methylation capacity and adversely affect the P21 gene in arsenic trioxide plant workers. Arsenic Trioxide 136-152 arsenite methyltransferase Homo sapiens 58-63 33549147-13 2021 Urine PMI could be a monitoring index for chronic AEs of ATO, and the SNPs of AS3MT gene should be considered when determining the dosage of ATO. Arsenic Trioxide 141-144 arsenite methyltransferase Homo sapiens 78-83 32677488-4 2020 Generally, ATO can be rapidly converted into trivalent methylated metabolites by arsenic (+3 oxidation state) methyltransferase (AS3MT) mostly in liver and redistributed to bloodstream of APL patients who receiving ATO treatment, thereby leading to a balance between cytotoxicity and differentiation, which is proposed to be the key event in successful treatment of APL. Arsenic Trioxide 11-14 arsenite methyltransferase Homo sapiens 81-127 32677488-4 2020 Generally, ATO can be rapidly converted into trivalent methylated metabolites by arsenic (+3 oxidation state) methyltransferase (AS3MT) mostly in liver and redistributed to bloodstream of APL patients who receiving ATO treatment, thereby leading to a balance between cytotoxicity and differentiation, which is proposed to be the key event in successful treatment of APL. Arsenic Trioxide 11-14 arsenite methyltransferase Homo sapiens 129-134 32677488-4 2020 Generally, ATO can be rapidly converted into trivalent methylated metabolites by arsenic (+3 oxidation state) methyltransferase (AS3MT) mostly in liver and redistributed to bloodstream of APL patients who receiving ATO treatment, thereby leading to a balance between cytotoxicity and differentiation, which is proposed to be the key event in successful treatment of APL. Arsenic Trioxide 215-218 arsenite methyltransferase Homo sapiens 129-134 32677488-5 2020 In this review, we comprehensively discussed possible roles of AS3MT and methylated arsenic metabolites in APL therapy, so as to reveal the association between individual differences of AS3MT expression and activity with the therapeutic efficacy of ATO in APL patients. Arsenic Trioxide 249-252 arsenite methyltransferase Homo sapiens 186-191 32112223-1 2020 Polymorphisms in arsenic (+ 3 oxidation state) methyltransferase (AS3MT) have been shown to be related to interindividual variations in arsenic metabolism and to influence adverse health effects in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide (As2O3). Arsenic Trioxide 255-271 arsenite methyltransferase Homo sapiens 66-71 32112223-0 2020 Polymorphisms in arsenic (+ 3 oxidation state) methyltransferase (AS3MT) predict the occurrence of hyperleukocytosis and arsenic metabolism in APL patients treated with As2O3. Arsenic Trioxide 169-174 arsenite methyltransferase Homo sapiens 66-71 32112223-1 2020 Polymorphisms in arsenic (+ 3 oxidation state) methyltransferase (AS3MT) have been shown to be related to interindividual variations in arsenic metabolism and to influence adverse health effects in acute promyelocytic leukemia (APL) patients treated with arsenic trioxide (As2O3). Arsenic Trioxide 273-278 arsenite methyltransferase Homo sapiens 66-71 32112223-9 2020 These results indicated that AS3MT 14215 (rs3740390) might be used as an indicator for predicting the occurrence of hyperleukocytosis in APL patients treated with As2O3. Arsenic Trioxide 163-168 arsenite methyltransferase Homo sapiens 29-34 30376134-0 2018 AS3MT Polymorphisms, Arsenic Metabolism, and the Hematological and Biochemical Values in APL Patients Treated with Arsenic Trioxide. Arsenic Trioxide 115-131 arsenite methyltransferase Homo sapiens 0-5 31330140-10 2019 Our data promotes the realization that AS3MT 35587 (rs11191453), 35991 (rs10748835), especially their joint genotypes 35991 (rs10748835) AA / 35587 (rs11191453) TC+CC, is a novel predictive biomarker for the therapeutic efficacy of As2O3 in the treatment of APL. Arsenic Trioxide 232-237 arsenite methyltransferase Homo sapiens 39-44 30376134-8 2018 These results indicate that inherent genetic information of the AS3MT rs3740390 genotypes is a novel predicted or evaluated target for As2O3-induced side effects and therapeutic efficacy for the treatment of APL. Arsenic Trioxide 135-140 arsenite methyltransferase Homo sapiens 64-69 29774349-1 2018 Arsenic (+3 oxidation state) methyltransferase (AS3MT) is a key enzyme responsible for arsenic metabolism in humans, which facilitates conversion of arsenic trioxide (As2O3) to more reactive metabolites such as monomethylarsonous acid (MMAIII) and dimethylarsinous acid (DMAIII). Arsenic Trioxide 149-165 arsenite methyltransferase Homo sapiens 0-46 29774349-1 2018 Arsenic (+3 oxidation state) methyltransferase (AS3MT) is a key enzyme responsible for arsenic metabolism in humans, which facilitates conversion of arsenic trioxide (As2O3) to more reactive metabolites such as monomethylarsonous acid (MMAIII) and dimethylarsinous acid (DMAIII). Arsenic Trioxide 149-165 arsenite methyltransferase Homo sapiens 48-53 29774349-1 2018 Arsenic (+3 oxidation state) methyltransferase (AS3MT) is a key enzyme responsible for arsenic metabolism in humans, which facilitates conversion of arsenic trioxide (As2O3) to more reactive metabolites such as monomethylarsonous acid (MMAIII) and dimethylarsinous acid (DMAIII). Arsenic Trioxide 167-172 arsenite methyltransferase Homo sapiens 0-46 29774349-1 2018 Arsenic (+3 oxidation state) methyltransferase (AS3MT) is a key enzyme responsible for arsenic metabolism in humans, which facilitates conversion of arsenic trioxide (As2O3) to more reactive metabolites such as monomethylarsonous acid (MMAIII) and dimethylarsinous acid (DMAIII). Arsenic Trioxide 167-172 arsenite methyltransferase Homo sapiens 48-53 29774349-6 2018 These findings indicate that the therapeutic efficacy of As2O3 (i.e., iAsIII) in APL patients is probably associated with the production of methylated arsenic metabolites (i.e., MMAIII and DMAIII) by AS3MT. Arsenic Trioxide 57-62 arsenite methyltransferase Homo sapiens 200-205